Stocktoria
Lifevantage Corp LFVN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-09-12
Lifevantage Corp statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 80.4% | 79.3% | 79.7% | 81.5% | 82.7% |
| Operating margin | 5.3% | 2.2% | 2.0% | 3.7% | 8.0% |
| Net margin | 4.3% | 1.5% | 1.2% | 1.5% | 5.9% |
| FCF margin | 4.6% | 5.0% | 1.8% | 3.1% | 5.7% |
| Return on assets | 13.6% | 4.9% | 3.8% | 4.4% | 16.4% |
| Return on equity | 28.3% | 11.3% | 7.3% | 9.9% | 35.0% |
| Current ratio | 1.87 | 1.69 | 2.26 | 1.83 | 1.91 |
| Revenue growth | 14.2% | -6.2% | 3.4% | -6.3% | -5.5% |
Source: SEC EDGAR filings · CIK 0000849146 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.